TherapeuticsMD, Inc. (NASDAQ:TXMD) shares were up 3.2% during mid-day trading on Wednesday . The company traded as high as $5.64 and last traded at $5.45. Approximately 870,881 shares traded hands during trading, a decline of 53% from the average daily volume of 1,851,075 shares. The stock had previously closed at $5.63.

A number of research analysts have issued reports on TXMD shares. BidaskClub lowered TherapeuticsMD from a “sell” rating to a “strong sell” rating in a research report on Friday, October 13th. Oppenheimer set a $10.00 price objective on TherapeuticsMD and gave the company a “buy” rating in a report on Monday, October 16th. Cowen restated an “outperform” rating and issued a $16.00 price objective (up previously from $13.00) on shares of TherapeuticsMD in a report on Monday, November 6th. Cantor Fitzgerald restated a “buy” rating and issued a $31.00 price objective on shares of TherapeuticsMD in a report on Wednesday, November 29th. Finally, Noble Financial restated a “buy” rating on shares of TherapeuticsMD in a report on Thursday, November 30th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $14.50.

The firm has a market cap of $1,190.00, a price-to-earnings ratio of -14.05 and a beta of 0.99.

In other news, Director Tommy G. Thompson acquired 5,000 shares of the business’s stock in a transaction dated Friday, December 8th. The stock was acquired at an average price of $6.21 per share, for a total transaction of $31,050.00. Following the completion of the acquisition, the director now directly owns 3,555 shares in the company, valued at approximately $22,076.55. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 23.92% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in TXMD. Amalgamated Bank lifted its holdings in shares of TherapeuticsMD by 7.2% during the second quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock valued at $104,000 after purchasing an additional 1,322 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of TherapeuticsMD by 3.9% during the second quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock valued at $114,000 after purchasing an additional 818 shares during the last quarter. Edge Wealth Management LLC lifted its holdings in shares of TherapeuticsMD by 2,500.0% during the fourth quarter. Edge Wealth Management LLC now owns 20,800 shares of the company’s stock valued at $125,000 after purchasing an additional 20,000 shares during the last quarter. Virtu KCG Holdings LLC purchased a new stake in shares of TherapeuticsMD during the second quarter valued at $157,000. Finally, Quantbot Technologies LP purchased a new stake in shares of TherapeuticsMD during the third quarter valued at $189,000. 73.86% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “TherapeuticsMD (TXMD) Trading Up -3.2%” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.watchlistnews.com/therapeuticsmd-txmd-trading-up-3-2/1851837.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.